Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

CKS Updates - February 2021

During February 2021 Clinical Knowledge Summaries were published or updated in the following areas.

All of the topics have been reviewed and updated in keeping with current guidance with minor layout changes. The two Contraception topics have been updated in line with Faculty of Sexual and Reproductive Healthcare (FSRH) guidance and references to some retired QOF indicators have been removed.

Action: Clinicians who see patients with any of these conditions may find the new and updated information useful when reviewing current clinical practice.

Share 'CKS Updates - February 2021' on Email Share 'CKS Updates - February 2021' on Delicious Share 'CKS Updates - February 2021' on Digg Share 'CKS Updates - February 2021' on Facebook Share 'CKS Updates - February 2021' on reddit Share 'CKS Updates - February 2021' on Twitter

NICE Guidance - February 2021

The National Institute for Health and Care Excellence (NICE) have published new or updated guidance for the month of February 2021. This month is one technology appraisal that impacts upon primary care.

The Dapagliflozin for treating chronic heart failure with reduced ejection fraction technology appraisal has been published. This treatment is recommended as an option for treating symptomatic chronic heart failure with reduced ejection fraction in adults, only if it is used as an add-on to optimised standard care with:

  • angiotensin-converting enzyme (ACE) inhibitors or angiotensin‑2 receptor blockers (ARBs), with beta blockers and, if tolerated, mineralocorticoid receptor antagonists (MRAs), or
  • sacubitril valsartan, with beta blockers and, if tolerated, MRAs

It is also noted that this treatment should only be started on the advice of a heart failure specialist.

Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.

Share 'NICE Guidance - February 2021' on Email Share 'NICE Guidance - February 2021' on Delicious Share 'NICE Guidance - February 2021' on Digg Share 'NICE Guidance - February 2021' on Facebook Share 'NICE Guidance - February 2021' on reddit Share 'NICE Guidance - February 2021' on Twitter

Drug Safety Update - February 2021

The Medicines and Healthcare products Regulatory Agency (MHRA) has published Drug Safety Update for February 2021 (PDF).

This month readers are advised of further restrictions on the use of ulipristal acetate (Esmya®) for uterine fibroids due to the risk of serious liver injury. The temporary suspension has been lifted but it is recommended that this medicine should only be used for intermittent treatment of moderate to severe symptoms before the menopause and when surgical procedures (including uterine fibroid embolisation) are not suitable or have failed.

Readers are also notified that pregabalin (Lyrica®) has been linked with infrequent reports of severe respiratory depression, including some cases without the presence of concomitant opioid medicines. Patients considered at higher risk of this complication include those with respiratory disease, neurological disease, renal impairment, those using concomitant CNS depressants and people older than 65 years. In such patients a more cautious introduction to this medication may be prudent and adjustments in dose or dosing regimen may be necessary.

An increased risk of acute adrenal insufficiency in children has also been identified when switching from hydrocortisone tablet formulations to granules (Alkindi®). During such switches, parents or carers should be informed of the need to be extra vigilant for symptoms of adrenal insufficiency.

This issue also contains information about the newly launched Safer Medicines in Pregnancy and Breastfeeding Consortium. This is a partnership of 16 leading organisations working together to improve the health information available to women who are thinking about becoming pregnant, are pregnant, or are breastfeeding, especially relating to the medicines they take. To support this work healthcare professionals are being asked to report inconsistencies in UK advice on use of individual or classes of medicines used in pregnancy or breastfeeding via the address on the consortium's webpage.

Finally in this issue is a summary of advice recently issued by the MHRA relating to coronavirus (COVID-19) vaccines and medicines as well as the summary of letters to healthcare professionals sent in January.

Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.

Share 'Drug Safety Update - February 2021' on Email Share 'Drug Safety Update - February 2021' on Delicious Share 'Drug Safety Update - February 2021' on Digg Share 'Drug Safety Update - February 2021' on Facebook Share 'Drug Safety Update - February 2021' on reddit Share 'Drug Safety Update - February 2021' on Twitter

CKS Updates - January 2021

During January 2021 Clinical Knowledge Summaries were published or updated in the following areas.

The Mental health in students topic is new. All of the other topics have been reviewed and updated in keeping with current NICE guidance with minor layout changes. The Anticoagulation - oral topic now includes a section on monitoring people taking anticoagulants during the COVID-19 pandemic in line with MHRA recommendations.

Action: Clinicians who see patients with any of these conditions may find the new and updated information useful when reviewing current clinical practice.

Share 'CKS Updates - January 2021' on Email Share 'CKS Updates - January 2021' on Delicious Share 'CKS Updates - January 2021' on Digg Share 'CKS Updates - January 2021' on Facebook Share 'CKS Updates - January 2021' on reddit Share 'CKS Updates - January 2021' on Twitter

NICE Guidance - January 2021

The National Institute for Health and Care Excellence (NICE) have published new or updated guidance for the month of January 2021. This month is one evidence summary that impacts upon primary care.

The Antimicrobial prescribing: delafloxacin for acute bacterial skin and skin structure infections evidence summary has been published. The likely place in therapy for delafloxacin is as an option for adults needing hospital treatment for severe acute bacterial skin and skin structure infections (ABSSSI), primarily cellulitis or erysipelas, abscesses and wound infections, when standard oral and intravenous treatments are not suitable. Intravenous treatment may be switched to oral treatment after 3 days if possible. It would be expected that any necessary completion of treatment is provided on discharge.

Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.

Share 'NICE Guidance - January 2021' on Email Share 'NICE Guidance - January 2021' on Delicious Share 'NICE Guidance - January 2021' on Digg Share 'NICE Guidance - January 2021' on Facebook Share 'NICE Guidance - January 2021' on reddit Share 'NICE Guidance - January 2021' on Twitter

« Older Posts

Prescribing Advice for GPs is powered by ClassicPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.

vipers